Evidence map›Paper›PMID 26363701›Full record

Trial reportThe lancet. Psychiatry2015

Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial.

Daniel Freeman, Felicity Waite, Helen Startup, Elissa Myers, Rachel Lister, Josephine McInerney, Allison G Harvey, John Geddes, Zenobia Zaiwalla, Ramon Luengo-Fernandez and 3 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The lancet. Psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06749444 (Cognitive Behavioral Therapy for Sleep and Circadian Disturbances), which is not on this map. Cited by 102 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 10 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06749444 narecruitingnot on this mapstarted 2024, after this paper: background citation

Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia

TypeinterventionalSponsorJimmi NielsenRan2024 to 2027Enrolled60ConditionsTreatment-refractory Schizophrenia, Treatment-resistant SchizophreniaArmsCBT-I, CBT
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 10 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Results of a pilot randomized controlled trial of CBT-I for veterans with serious mental illness and insomnia.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Daniel FreemanDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. Electronic address: daniel.freeman@psych.ox.ac.uk.
Felicity WaiteDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Helen StartupDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK; Sussex Partnership NHS Trust, Worthing, West Sussex.
Elissa MyersDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Rachel ListerDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Josephine McInerneyDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Allison G HarveyDepartment of Psychology, University of California, Berkeley, CA, USA.
John GeddesDepartment of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
Zenobia ZaiwallaOxford Non-Respiratory Sleep Disorder Service, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, UK.
Ramon Luengo-FernandezHealth Economics Research Centre, Department of Public Health, University of Oxford, Oxford, UK.
Russell FosterSleep and Circadian Neurosciences Institute, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Lei CliftonCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Ly-Mee YuNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Warneford Hospital · GBUniversity of Oxford · GBJohn Radcliffe Hospital · GBNuffield Orthopaedic Centre · GBUniversity of California, Berkeley · US

Funding

Department of Health PB-PG-0211-10007Medical Research CouncilWellcome Trust 098461Wellcome Trust 098461/Z/12/Z
6 · The paper itself

Abstract

backgroundSleep disturbance occurs in most patients with delusions or hallucinations and should be treated as a clinical problem in its own right. However, cognitive behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been tested in this patient population. We aimed to pilot procedures for a randomised trial testing CBT for sleep problems in patients with current psychotic experiences, and to provide a preliminary assessment of potential benefit.

methodsWe did this prospective, assessor-blind, randomised controlled pilot trial (Better Sleep Trial [BEST]) at two mental health centres in the UK. Patients (aged 18-65 years) with persistent distressing delusions or hallucinations in the context of insomnia and a schizophrenia spectrum diagnosis were randomly assigned (1:1), via a web-based randomisation system with minimisation to balance for sex, insomnia severity, and psychotic experiences, to receive either eight sessions of CBT plus standard care (medication and contact with the local clinical team) or standard care alone. Research assessors were masked to group allocation. Assessment of outcome was done at weeks 0, 12 (post-treatment), and 24 (follow-up). The primary efficacy outcomes were insomnia assessed by the Insomnia Severity Index (ISI) and delusions and hallucinations assessed by the Psychotic Symptoms Rating Scale (PSYRATS) at week 12. We did analysis by intention to treat, with an aim to provide confidence interval estimation of treatment effects. This study is registered with ISRCTN, number 33695128.

findingsBetween Dec 14, 2012, and May 22, 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 50 patients to receive CBT plus standard care (n=24) or standard care alone (n=26). The last assessments were completed on Feb 10, 2015. 48 (96%) patients provided follow-up data. 23 (96%) patients offered CBT took up the intervention. Compared with standard care, CBT led to reductions in insomnia in the large effect size range at week 12 (adjusted mean difference 6.1, 95% CI 3.0-9.2, effect size d=1.9). By week 12, nine (41%) of 22 patients receiving CBT and one (4%) of 25 patients receiving standard care alone no longer had insomnia, with ISI scores lower than the cutoff for insomnia. The treatment effect estimation for CBT covered a range from reducing but also increasing delusions (adjusted mean difference 0.3, 95% CI -2.0 to 2.6) and hallucinations (-1.9, -6.5 to 2.7). Three patients, all in the CBT group, had five adverse events, although none were regarded as related to study treatment.

interpretationOur findings show that CBT for insomnia might be highly effective for improving sleep in patients with persistent delusions or hallucinations. A larger, suitably powered phase 3 study is now needed to provide a precise estimate of the effects of CBT for sleep problems, both on sleep and psychotic experiences.

fundingResearch for Patient Benefit Programme, National Institute for Health Research.

Indexed as

Cognitive Behavioral TherapyAdultDelusionsDouble-Blind MethodFemaleHallucinationsHumansMaleMiddle AgedProspective StudiesSleep Wake DisordersTreatment Outcome

Identifiers

PMID26363701
PMCPMC4641164
OpenAlexW2165478117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.